NTHI Executives Purchase $629,000 in Company Stock Following Positive Clinical Data

NeOnc Technologies (NTHI) disclosed that its top executives have made significant open-market stock purchases totaling approximately $629,000. These investments follow the company's recent announcement of positive Phase 2a clinical trial results for its lead drug candidate, NEO100, signaling strong insider confidence.

Key Details

• Total Investment: CEO Amir Heshmatpour and Chief Medical Officer Dr. Thomas C. Chen collectively purchased 160,016 shares for approximately $629,000 since the trial results were announced on August 12, 2026.
• CEO Purchases: Mr. Heshmatpour acquired a total of 111,000 shares for ~$418,700, with the most recent purchase of 35,000 shares occurring on September 15, 2026, for ~$115,400.
• Strategic Context: The executive stock purchases were made following the announcement that the NEO100-01 Phase 2a study met its primary endpoint for treating central nervous system (CNS) cancers.